| Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households (NCT03969212) | Hoffmann-La Roche | 2019-10-10 |
| The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (NCT03898986) | Stanford University | 2019-10-08 |
| Retrospective Observational Study on the Epidemiological Characteristics of Influenza Patients (NCT04110990) | University Hospital, Strasbourg, France | 2019-10-01 |
| Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (NCT04109222) | Sanofi Pasteur, a Sanofi Company | 2019-09-30 |
| Response to Influenza Vaccine During Pregnancy (NCT03888989) | Stanford University | 2019-09-30 |
| Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (NCT04091880) | China National Biotec Group Company Limited | 2019-09-26 |
| Performance Feedback in Health Care (NCT04579614) | Kaiser Permanente | 2019-09-23 |
| Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects (NCT04074928) | Seqirus | 2019-09-06 |
| Recombinant Influenza Vaccination in U.S. Nursing Homes (NCT03965195) | Insight Therapeutics, LLC | 2019-07-20 |
| Flublok or Fluzone With Advax-CpG55.2 or AF03 (NCT03945825) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-10 |
| Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray (NCT04146623) | Codagenix, Inc | 2019-05-07 |
| Early Flu Shots in SOT (NCT03327987) | University Health Network, Toronto | 2019-05-07 |
| Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route (NCT03845231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-29 |
| Phase 1 Study of ATR-002 (NCT04385420) | Atriva Therapeutics GmbH | 2019-04-24 |
| Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (NCT03777163) | Butantan Institute | 2019-04-22 |
| Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood (NCT03884296) | Stanford University | 2019-04-15 |
| Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood (NCT03898973) | Stanford University | 2019-04-11 |
| Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults (NCT03880474) | Barinthus Biotherapeutics | 2019-03-18 |
| Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine (NCT03430089) | Sanofi Pasteur, a Sanofi Company | 2019-02-22 |
| Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season (NCT03754686) | Rambam Health Care Campus | 2019-02-10 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever (NCT03830684) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-02-01 |
| Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI (NCT03830905) | PHARMENTERPRISES LLC | 2019-01-31 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms (NCT03653364) | Hoffmann-La Roche | 2019-01-23 |
| Study of the Safety and Immunogenicity of NasoVAX Extension (NCT03760549) | Altimmune, Inc. | 2019-01-21 |
| Severe Influenza Trial of ARbidol (NCT03787459) | Capital Medical University | 2019-01-18 |
| Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service. (NCT04048369) | University Hospital, Clermont-Ferrand | 2019-01-17 |
| Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (NCT03765437) | Sanofi Pasteur, a Sanofi Company | 2019-01-15 |
| Biomarkers for the Prognosis of Influenza in Children (NCT03231995) | Hospices Civils de Lyon | 2019-01-15 |
| Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza (NCT03684044) | Hoffmann-La Roche | 2019-01-08 |
| Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals (NCT03816878) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-08 |
| Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults (NCT03743688) | Vanderbilt University Medical Center | 2018-12-04 |
| Extra-pulmonary Clinical Manifestations of Influenza Virus and Respiratory Syncitial Virus Infections (NCT03757546) | Poitiers University Hospital | 2018-12-03 |
| TITRE III: Influenza B Immunogenicity Investigation (NCT03753347) | British Columbia Centre for Disease Control | 2018-12-01 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms (NCT03629184) | Hoffmann-La Roche | 2018-11-20 |
| A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (NCT03734237) | Henry M. Jackson Foundation for the Advancement of Military Medicine | 2018-11-06 |
| CT18 Infant Influenza Priming Study in Vaccine Naive Infants (NCT03669627) | Canadian Immunization Research Network | 2018-11-01 |
| A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (NCT03718468) | Medigen Vaccine Biologics Corp. | 2018-10-30 |
| Reducing the Burden of Influenza After Solid-Organ Transplantation (NCT03699839) | Oriol Manuel | 2018-10-26 |
| Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months (NCT03704740) | SK Bioscience Co., Ltd. | 2018-10-25 |
| The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics (NCT03686514) | Emory University | 2018-10-22 |
| Safety of LAIV4 in Children With Asthma (NCT03600428) | Vanderbilt University Medical Center | 2018-10-15 |
| Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System (NCT03950986) | Atlanta VA Medical Center | 2018-10-15 |
| Pregnancy, Arsenic and Immune Response (NCT03930017) | Johns Hopkins Bloomberg School of Public Health | 2018-10-14 |
| A Clinical Trial of A Quadrivalent Influenza Vaccine (NCT03744104) | Shanghai Institute Of Biological Products | 2018-10-11 |
| Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above (NCT05406180) | Sanofi | 2018-10-10 |
| Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (NCT03698279) | Sanofi Pasteur, a Sanofi Company | 2018-10-09 |
| Patient Portal - Flu Reminder Recall (NCT03666026) | University of California, Los Angeles | 2018-10-02 |
| Development of Childhood Anti-Influenza Immunity (NCT03673345) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-25 |
| Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil (NCT03330899) | Butantan Institute | 2018-09-24 |
| The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers. (NCT03679143) | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 2018-09-20 |
| Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring (NCT04460781) | Sanofi Pasteur, a Sanofi Company | 2018-09-17 |
| Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years (NCT03694392) | Kaiser Permanente | 2018-09-16 |
| Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP (NCT03722589) | Centers for Disease Control and Prevention | 2018-09-12 |
| Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (NCT03617523) | Sanofi Pasteur, a Sanofi Company | 2018-09-10 |
| Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor (NCT03590808) | Seoul National University Hospital | 2018-09-01 |
| Gene Signatures of Influenza Vaccine Responses in Older Adults (NCT03603509) | Mayo Clinic | 2018-08-27 |
| H3N2 M2SR in Pediatric Population (NCT03553940) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-15 |
| A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine (NCT03450915) | BiondVax Pharmaceuticals ltd. | 2018-08-01 |
| Invasive Pulmonary Aspergillosis and Severe Influenza (NCT04232956) | University Hospital, Brest | 2018-07-27 |
| Adjuvanted Influenza Vaccination Year 2 Follow-On Survey (NCT03599739) | Insight Therapeutics, LLC | 2018-07-13 |
| Nasal and Systemic Immune Responses to Nasal Influenza Vaccine (NCT04110366) | Imperial College Healthcare NHS Trust | 2018-06-14 |
| Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects (NCT03594890) | Osivax | 2018-06-12 |
| D2560C00015 FluMist Annual Safety Study 2018 (NCT03564444) | MedImmune LLC | 2018-06-06 |
| Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (NCT03058692) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-04-09 |
| Digital Online Consultations - Effects on Antibiotic Prescribing and Health Care Utilization in Primary Care (NCT03474887) | Region Skane | 2018-03-30 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 (NCT03318315) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-20 |
| Kagocel® for the Prevention of ARVI and Influenza in Young People (NCT04626622) | Nearmedic Plus LLC | 2018-02-15 |
| Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections (NCT03455491) | PHARMENTERPRISES LLC | 2018-02-12 |
| Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (NCT03437304) | Eurocine Vaccines AB | 2018-02-09 |
| A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza (NCT03394209) | Capital Medical University | 2018-02-06 |
| Influenza Management With Polyherbal Formulation (NCT03365336) | Composite Interceptive Med Science | 2018-02-01 |
| Nosocomial Influenza Surveillance 2018 - 2022 (NCT03413228) | Hospices Civils de Lyon | 2018-02-01 |
| Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine (NCT03391193) | Sanofi Pasteur, a Sanofi Company | 2017-12-19 |
| Age and Response to Flu Vaccines (NCT03328325) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-14 |
| Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration (NCT03372967) | American Pharmacists Association Foundation | 2017-12-12 |
| Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza (NCT05095545) | Viriom | 2017-11-13 |
| Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years (NCT03344029) | Sanofi | 2017-11-03 |
| Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults (NCT03186781) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-10-25 |
| Immune Responses in Health Care Personnel (NCT03323112) | Finnish Institute for Health and Welfare | 2017-10-18 |
| The Oakland Men's Health Disparities Study (NCT03481270) | Stanford University | 2017-10-14 |
| Improved Novel VaccIne CombinaTion InflUenza Study (NCT03300362) | Barinthus Biotherapeutics | 2017-10-13 |
| Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (NCT03300050) | PATH | 2017-10-10 |
| Vaccination Education Through Pharmacists and Senior Centers (VEPSC) (NCT03239665) | Rutgers, The State University of New Jersey | 2017-10-10 |
| FluSAFE: Flu SMS Alerts to Freeze Exposure (NCT03274310) | Columbia University | 2017-10-06 |
| Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers (NCT04611061) | Nearmedic Plus LLC | 2017-10-02 |
| Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls (NCT03104790) | Public Health England | 2017-10-02 |
| Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus (NCT03367624) | Central Hospital, Nancy, France | 2017-10-01 |
| A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine (NCT03581903) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-19 |
| Effects of Aging on Primary and Secondary Vaccine Responses (NCT03312699) | Stanford University | 2017-09-19 |
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX (NCT03232567) | Altimmune, Inc. | 2017-09-18 |
| Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) (NCT03293498) | Novavax | 2017-09-18 |
| Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years (NCT03233217) | Sanofi Pasteur, a Sanofi Company | 2017-09-15 |
| Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines (NCT03308825) | Sanofi Pasteur, a Sanofi Company | 2017-09-11 |
| Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US (NCT03282240) | Sanofi Pasteur, a Sanofi Company | 2017-09-08 |
| Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults (NCT03301051) | Medicago | 2017-08-31 |
| Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction. (NCT03248960) | Ellume Pty Ltd | 2017-07-27 |
| Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults (NCT03390166) | Mahidol University | 2017-07-24 |
| Pediatric and Ambulatory Research in Infectious Diseases (NCT04471493) | Association Clinique Thérapeutique Infantile du val de Marne | 2017-06-26 |
| Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (NCT03158038) | MedImmune LLC | 2017-05-30 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers (NCT03459391) | PHARMENTERPRISES LLC | 2017-05-22 |